Comparative study of tolerability and efficacy of haloperidol versus olanzapine in schizophrenia
- Conditions
- Health Condition 1: null- Schizophrenia - Paranoid
- Registration Number
- CTRI/2015/02/005575
- Lead Sponsor
- Government Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Diagnosis of paranoid schizophrenia according to ICD-10
Attending the outpatient clinic or those admitted to the inpatient services
Patients in the age group of 18 to 65 years Patients having normal intelligence
Patients who were willing to give written informed consent were included.
Patients should have been drug naïve for at least 2 weeks prior to the baseline assessments.
Patients with past history of poor response or hypersensitivity to olanzapine or haloperidol were excluded.
We also excluded patients with co-morbid substance related disorders except nicotine and caffeine
Patients with chronic medical illness, neurological disorders, head injury, tumors, movement disorder, pregnant and lactating females.
Any other condition which affected the quality of life of the patients was an exclusion criterion.
Patients who were unwilling to participate in the study were also excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Score on Positive and negative syndrome scale for schizophrenia <br/ ><br>2. Score on WHO QoL Bref Hindi. <br/ ><br>3. Side effects like extrapyramidal symptoms, metabolic parameters, sexual side effectsTimepoint: 1. Score on Positive and negative syndrome scale for schizophrenia <br/ ><br>2. Score on WHO QoL Bref Hindi. <br/ ><br>3. Side effects like extrapyramidal symptoms, metabolic parameters, sexual side effects
- Secondary Outcome Measures
Name Time Method serum electrolytes <br/ ><br>QTc intervalTimepoint: baseline <br/ ><br>1 month <br/ ><br>3 months <br/ ><br>6 months